Evidence map›Paper›PMID 40185723›Full record

ArticleNature communications2025

A human model to deconvolve genotype-phenotype causations in lung squamous cell carcinoma.

Julia Ogden, Robert Sellers, Sudhakar Sahoo, Anthony Oojageer, Anshuman Chaturvedi, Caroline Dive, Carlos Lopez-Garcia

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia OgdenCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom.
Robert SellersCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom.
Sudhakar SahooCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom.
Anthony OojageerCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom.
Anshuman ChaturvediDepartment of Histopathology, The Christie Hospital, Wilmslow Road, Manchester, M20 4BX, United Kingdom.
Caroline DiveCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom.ORCID http://orcid.org/0000-0002-1726-8850
Carlos Lopez-GarciaCancer Research UK Manchester Institute, Wilmslow Road, M20 4BX, Manchester, United Kingdom. carlos.lopezgarcia@cruk.manchester.ac.uk.ORCID http://orcid.org/0000-0001-9848-8216

Funding

Cancer Research UK (CRUK) A20971Cancer Research UK (CRUK) A25146Cancer Research UK (CRUK) C5759National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/W001284/1National Centre for the Replacement Refinement and Reduction of Animals in Research (NC3Rs) NC/W001284/1Rosetrees Trust M767
6 · The paper itself

Abstract

Tractable, patient-relevant models are needed to investigate cancer progression and heterogeneity. Here, we report an alternative in vitro model of lung squamous cell carcinoma (LUSC) using primary human bronchial epithelial cells (hBECs) from three healthy donors. The co-operation of ubiquitous alterations (TP53 and CDKN2A loss) and components of commonly deregulated pathways including squamous differentiation (SOX2), PI3K signalling (PTEN) and the oxidative stress response (KEAP1) is investigated by generating hBECs harbouring cumulative alterations. Our analyses confirms that SOX2-overexpression initiates early preinvasive LUSC stages, and co-operation with the oxidative stress response and PI3K pathways to drive more aggressive phenotypes, with expansion of cells expressing LUSC biomarkers and invasive properties. This cooperation is consistent with the classical LUSC subtype. Importantly, we connect pathway dysregulation with gene expression changes associated with cell-intrinsic processes and immunomodulation. Our approach constitutes a powerful system to model LUSC and unravel genotype-phenotype causations of clinical relevance.

Indexed as

Carcinoma, Squamous CellLung NeoplasmsBronchiCyclin-Dependent Kinase Inhibitor p16Epithelial CellsGene Expression Regulation, NeoplasticGenetic Association StudiesGenotypeHumansKelch-Like ECH-Associated Protein 1Models, BiologicalOxidative StressPhenotypePhosphatidylinositol 3-KinasesPTEN PhosphohydrolaseSignal TransductionCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16KEAP1 protein, humanKelch-Like ECH-Associated Protein 1Phosphatidylinositol 3-KinasesPTEN PhosphohydrolasePTEN protein, humanSOX2 protein, humanSOXB1 Transcription FactorsTP53 protein, humanTumor Suppressor Protein p53

Identifiers

PMID40185723
PMCPMC11971459

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.